目的 分析阿昔替尼致不良反應(yīng)（ADR）的臨床表現(xiàn)和特點(diǎn)，為其臨床安全用藥提供參考。方法 檢索PubMed、Web of Science、中國知網(wǎng)數(shù)據(jù)庫和萬方數(shù)據(jù)庫關(guān)于阿昔替尼的不良反應(yīng)文獻(xiàn)并進(jìn)行分析。結(jié)果 阿昔替尼致ADR的個(gè)案報(bào)道18例；年齡分布以50～70歲居多（11例，61.11%）；ADR多發(fā)生在用藥后180 d內(nèi)（13例，72.22%）；阿昔替尼致ADR累及器官/系統(tǒng)主要以消化系統(tǒng)（6例，33.33%）和血液系統(tǒng)（6例，33.33%）為主。結(jié)論 阿昔替尼引起的不良反應(yīng)可累及全身多個(gè)系統(tǒng)，臨床使用時(shí)需加強(qiáng)用藥監(jiān)測(cè)，警惕不良反應(yīng)的發(fā)生。

Objective To analyze the clinical manifestations and characteristics of adverse drug reaction (ADR) induced by Axitinib in order to provide references for rational drug use. Methods PubMed, Web of Science, CNKI and Wan-fang databases were searched for ADR induced by Axitinib, and the collected literatures were further analyzed statistically. Results Eighteen ADR were indentified and included. Patients of 50 to 70 years showed the highest incidence (n =11, 61.11%). ADR of axitinib frequently occurred within 180 days after medication (n=13, 72.22%). Axitinib induced ADR were mainly digestive system (n =6, 33.33%) and hematological system (n =6, 33.33%). Conclusion The ADR induced by axitinib may involve multiple systems. Physicians and pharmacists should pay more attentions to the safety monitoring of axitinib during medication, be alert to the occurrence of ADR.

R979.1

天津市教委科研計(jì)劃項(xiàng)目（2019KJ187）